AtheroGenics To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference On February 14, 2006
ATLANTA, Feb. 7 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., President and Chief Executive Officer, will present a company overview and update at the BIO CEO & Investor Conference on Tuesday, February 14, 2006, at 10:30 a.m. EST at the Waldorf Astoria Hotel in New York City.
(LOGO: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGO)
A live audio webcast of the presentation will be available via a link on the Company's Investor Relations website at www.atherogenics.com, under the "Investor Calendar" tab. A replay of the presentation will be available for 14 days.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit www.atherogenics.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20040730/ATATHEROGENICSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAtheroGenics, Inc.CONTACT: Donna Glasky, Corporate Communications of AtheroGenics, Inc.,+1-678-336-2517, or investor@atherogenics.com; or Investor Relations,Lilian Stern of Stern Investor Relations, +1-212-362-1200, orlilian@sternir.com; or Media Relations, Katie Brazel of Fleishman Hillard,+1-404-739-0150, or brazelk@fleishman.com
Web site: http://www.atherogenics.com//